Guangsheng Hall: Innovative hepatitis B drugs are still in the research and development stage.

Guangsheng Hall announced that the company's stock has experienced abnormal fluctuations in trading from April 1st to April 3rd, 2026, with the closing price deviation exceeding 30% for three consecutive trading days. The company's innovative drug for hepatitis B is still in the research stage. The research and development of innovative drugs have a long cycle, high investment, and high risk, and are easily influenced by various factors. There is a risk of clinical research results not meeting expectations or even failing. The uncertainty of whether it can be approved for listing in the future, will not have a significant impact on the company's performance in the short term. Investors are advised to make decisions carefully and be cautious about investment risks.